Senseonics Holdings, Inc. is set to present its advanced Eversense® 365 Continuous Glucose Monitoring system at the upcoming American Diabetes Association’s 85th Scientific Sessions. The event, scheduled for June 21, 2025, will be held both in-person and virtually at the Marriott Marquis Chicago, offering a comprehensive insight into the latest developments in diabetes management technology.
Event Highlights and Key Announcements
During the session, company executives will delve into the features and benefits of the newly FDA-approved Eversense® 365 system, designed for adults aged 18 and older living with diabetes. The presentation will include expert commentary from Brian Hansen of Ascencia Diabetes Care, who will discuss the system’s commercial launch, and Gary Graf from Cotton-O’Neil Diabetes and Endocrinology Center, who will share firsthand experiences with the device and its insertion procedure.
Strategic Partnerships and Future Developments
Senseonics will also reveal its strategic collaboration with Sequel to integrate the Eversense® 365 with the twiist automated insulin delivery pump. This partnership aims to enhance the efficacy and user experience of continuous glucose monitoring systems. Additionally, the company will outline its roadmap for expanding its implantable CGM technology pipeline, signaling a commitment to innovation in diabetes care.
• Integration with twiist pump may streamline diabetes management
• Long-term implantable sensors reduce the need for frequent replacements
• Partnership with Sequel could accelerate market penetration
• Enhanced data communication with mobile apps improves user engagement
• Expansion of implantable CGM pipeline indicates robust R&D efforts
The live Q&A session will provide attendees with the opportunity to engage directly with Senseonics’ leadership and experts, fostering a deeper understanding of the Eversense® 365 system’s capabilities and future prospects. This interactive segment underscores Senseonics’ commitment to transparency and stakeholder engagement.
Senseonics, a leader in long-term implantable glucose monitoring technology, continues to innovate with products like Eversense® 365 and Eversense® E3, which offer seamless glucose data tracking via a smart transmitter and a mobile app. These advancements not only enhance the quality of life for individuals with diabetes but also position Senseonics at the forefront of medical technology in the diabetes community.
Attendees can register for the event through Senseonics’ official channels, ensuring access to the latest information and updates directly from the company. This initiative demonstrates Senseonics’ proactive approach in addressing the evolving needs of diabetes management through cutting-edge technology and strategic collaborations.
Advancements in continuous glucose monitoring, such as those presented by Senseonics, are crucial for improving diabetes care. By focusing on long-term, implantable solutions, the company addresses common challenges faced by users, including sensor durability and ease of use. The integration with automated insulin delivery systems represents a significant step towards more personalized and automated diabetes management, potentially reducing the burden on users and enhancing overall health outcomes.
Senseonics’ ongoing dedication to research and development, combined with strategic partnerships, positions the company to deliver innovative solutions that meet the complex needs of the global diabetes community. As diabetes prevalence continues to rise, the importance of reliable and user-friendly monitoring systems becomes increasingly critical, and Senseonics is well-equipped to lead the way in this essential area of healthcare.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
